- Home
- MDCX vs RLAY Comparison
MDCX vs RLAY Comparison
Compare MDCX & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDCX
- RLAY
- Stock Information
- Founded
- MDCX 2008
- RLAY 2015
- Country
- MDCX United States
- RLAY United States
- Employees
- MDCX N/A
- RLAY N/A
- Industry
- MDCX
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MDCX
- RLAY Health Care
- Exchange
- MDCX Nasdaq
- RLAY Nasdaq
- Market Cap
- MDCX 50.8M
- RLAY 803.4M
- IPO Year
- MDCX N/A
- RLAY 2020
- Fundamental
- Price
- MDCX $2.34
- RLAY $6.94
- Analyst Decision
- MDCX Strong Buy
- RLAY Strong Buy
- Analyst Count
- MDCX 2
- RLAY 8
- Target Price
- MDCX $23.50
- RLAY $17.25
- AVG Volume (30 Days)
- MDCX 338.8K
- RLAY 2.0M
- Earning Date
- MDCX 11-22-2025
- RLAY 11-06-2025
- Dividend Yield
- MDCX N/A
- RLAY N/A
- EPS Growth
- MDCX N/A
- RLAY N/A
- EPS
- MDCX N/A
- RLAY N/A
- Revenue
- MDCX N/A
- RLAY $8,355,000.00
- Revenue This Year
- MDCX N/A
- RLAY $27.30
- Revenue Next Year
- MDCX N/A
- RLAY $7.43
- P/E Ratio
- MDCX N/A
- RLAY N/A
- Revenue Growth
- MDCX N/A
- RLAY N/A
- 52 Week Low
- MDCX $1.79
- RLAY $1.78
- 52 Week High
- MDCX $8.94
- RLAY $7.64
- Technical
- Relative Strength Index (RSI)
- MDCX 47.40
- RLAY 59.49
- Support Level
- MDCX $2.34
- RLAY $6.30
- Resistance Level
- MDCX $2.60
- RLAY $7.42
- Average True Range (ATR)
- MDCX 0.20
- RLAY 0.46
- MACD
- MDCX -0.01
- RLAY -0.06
- Stochastic Oscillator
- MDCX 12.00
- RLAY 56.25
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).